Illumina (ILMN) Shares are Up 2.8%

Illumina (ILMN) : Traders are bullish on Illumina (ILMN) as it has outperformed the S&P 500 by a wide margin of 13.44% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 2.83%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.8% in the last 1 week, and is up 13.87% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Illumina Inc. is up 22.18% in the last 3-month period. Year-to-Date the stock performance stands at -10.57%. The stock has recorded a 20-day Moving Average of 4.08% and the 50-Day Moving Average is 13.54%.


Illumina (NASDAQ:ILMN): The stock opened at $171.83 on Friday but the bulls could not build on the opening and the stock topped out at $174.07 for the day. The stock traded down to $169.81 during the day, due to lack of any buying support eventually closed down at $171.67 with a loss of -0.41% for the day. The stock had closed at $172.37 on the previous day. The total traded volume was 1,015,440 shares.

Also, Argus Research maintains its view on Illumina (NASDAQ:ILMN) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. Argus Research raises the price target from $175 per share to $185 per share on Illumina . The rating by the firm was issued on August 8, 2016.

Illumina, Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems, consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms, reagent kits and scanning equipment. Its customers include genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories, pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research, including de novo sequencing, genetic variation analysis, epigenetics and targeted screening, among others. It also provides products and services for other life sciences applied markets, such as agrigenomics. It also offers Clarity Run Manager, Clarity LIMS Silver and Clarity LIMS Gold.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.